Jodie Schildkraut is a postdoctoral researcher and clinical project manager at the Centre for Infectious Diseases within the Radboud University Medical Center. In 2017, she completed her degree in Biomedical Sciences at the Radboud University with honors. She then performed her PhD at the Radboud University Medical centre in The Netherlands and was a visiting PhD student at the Molecular Immunity Unit at the University of Cambridge in the UK. During her PhD she focused on multiple aspects of nontuberculous mycobacterial disease, including epidemiology, mechanisms of antibiotic resistance, host-pathogen interactions and novel diagnostic methods. Following her PhD she shifted focus to clinical tuberculosis research within the UNITE4TB and PanACEA consortia. She also oversees coordination of the PORT trial (optimized dose rifampicin) conducted at study sites throughout Europe.
Dr Jodie Schildkraut
